Showing results (101-110 of 271) with videos related to

Sort By:
Pageof 28
Emerging Infectious Diseases|July 18, 2018
Outbreak of Trichinella T9 Infections Associated with Consumption of Bear Meat, JapanKatsushige Tada, Hiromichi Suzuki, Yosuke Sato, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|October 11, 2021
[A case of pembrolizumab-induced sclerosing cholangitis that was responsive to high-dose steroid therapy]Shigehiro Nagasawa, Masayuki Miyazaki, Yusuke Morita, et al.
Internal Medicine (Tokyo, Japan)|March 28, 2012
Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutationKosuke Tanaka, Akito Hata, Yoko Kida, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Tumor-infiltrating CD8+ T-cell numbers and serum C-reactive protein levels as a prognostic biomarker in hepatocellular carcinoma patients receiving atezolizumab plus bevacizumabAkifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, et al.
Molecular and Clinical Oncology|January 24, 2022
Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRIAkifumi Kuwano, Kosuke Tanaka, Masayoshi Yada, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|August 9, 2022
[A case of multiple osteonecrosis caused by acute-on-chronic pancreatitis]Yusuke Morita, Akifumi Kuwano, Shigehiro Nagasawa, et al.
Anticancer Research|September 26, 2025
Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective StudyAkifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, et al.
In Vivo (Athens, Greece)|June 27, 2024
Similar Efficacy Between Atezolizumab Plus Bevacizumab Versus Hepatic Arterial Infusion Chemotherapy For Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Cohort StudyAkifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, et al.
Experimental and Therapeutic Medicine|August 24, 2023
FIB‑4 index and serum α‑fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapyAkifumi Kuwano, Masayuki Miyazaki, Masayoshi Yada, et al.
Cancer Diagnosis & Prognosis|January 4, 2024
Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabAkifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, et al.
Pageof 28